99% CAS 1985606-14-1 Baloxavir Marboxil Raw Powder Baloxavir Baloxavir Marboxil Material Baloxavir Marboxil

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Baloxavir Marboxil
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Baloxavir Marboxil
• Name: Baloxavir Marboxil Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical;Anti-Flu;Anti-Viral
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No: 1985606-14-1
• Mf: C27h23f2n3o7s
• MW: 571.6
• Boiling Point: 712.8±70.0 °c
• Density: 1.57±0.1 g/cm3(Predicted)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

99% CAS 1985606-14-1 Baloxavir Marboxil Raw Powder Baloxavir Baloxavir Marboxil Material Baloxavir Marboxil

Product Description

Product Details

Product name	Baloxavir Marboxil
Cas number	1985606-14-1
Appearance	White powder
MF	C27H23F2N3O7S
MW	571.6

Baloxavir marboxil is a white crystalline powder. Baloxavir marboxil is a new hat-dependent endonuclease inhibitor that kills influenza viruses within 24 hours, but some symptoms can last longer. Baloxavir marboxil inhibits virus replication by different mechanisms from existing anti-flu drugs. Oseltamivir (tamiflu), which is snapped up during flu, Baloxavir marboxil usually takes 72 hours to work.
Unlike neuraminidase inhibitors such as oseltamivir (tamiflu), baloxavir marboxil prevents virus replication by inhibiting cap - dependent endonuclease activity of viral polymerases.

Application&Function

Baloxavir marboxil is used to treat influenza A and influenza B infections. The drug was initially approved for marketing in Japan in February 2018, and was approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza patients 12 years of age and older who have symptoms for no more than 48 hours. Baloxavir marboxil is a cap endonuclease inhibitor, which has a unique mechanism of action compared with the class of neuraminidase inhibitor drugs currently used to treat influenza infections.

Specification